Sign in
Active, not recruitingNo phase

Is Fat in the Liver a Marker of Post-Pregnancy Glycaemic Deterioration in Women With Gestational Diabetes?

Key facts

Who runs it
University Hospitals of North Midlands NHS Trust
Where
United Kingdom1 site in 1 countryChoose a country to see its sites
Trial code
Status
Active, not recruiting
People taking part
189 people enrolled
Started
5 May 2019
Expected to end
30 Dec 2026
Type of study
Observational
Treatments tested
  • MRI scan
Record updated
30 March 2026

Who can take part

Age
18 years and older
Sex
Women only
Healthy volunteers
Cannot take part
Show the full registry criteria (6)Hide the full registry criteria

Who can take part

  • Aged 18 and over
  • Pregnant women diagnosed with GDM based on OGTT

Who cannot take part

  • Women with known type 1 or type 2 diabetes prior to pregnancy
  • Women with known history of liver disease including alcoholic liver disease
  • Women unable or unwilling to consent to be part of the study
  • Women with contraindication to MRI

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

The aim of this study is to utilise ultrasound, using an established method for detecting NAFLD, to determine whether the presence of NAFLD in women with GDM, detected during routine scanning, is a marker of deterioration in glycaemic status post-partum. We propose to assess the relationship between NAFLD and surrogates for insulin resistance as well as glycaemic status, insulin sensitivity and β-cell function, after delivery.

Read full original descriptionShow less

The study is not seeking to compare the incidence of T2DM between those with and without NAFLD. This would require a longer follow-up and larger cohort size. Instead, it aims to quantify the degree of early deterioration of glycaemic status in these groups using insulin resistance markers. This is a clinically important issue as a greater level of insulin resistance would in itself trigger clinical intervention, including vigilant follow-up and empowerment for proactive healthy life style changes, which have been shown to prevent diabetes development .

The group in the trial

  • Pregnant women with GDM

    Ultrasound liver scan in addition to routine foetal assessment (antenatal) Metabolic profile blood tests, Oral Glucose Tolerance Test, ELF blood test, repeat liver ultrasound scan and MRI scan (post partum)

    Treatment: MRI scan

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Record updated
30 March 2026